Faster Paths To Biosimilar Equivalence: Turning New US & EU Guidance Into Development Advantage

Recent FDA biosimilar guidances and projections for EU biosimilar guidances emphasize analytical similarity and risk‑based justification, enabling developers to streamline or waive comparative clinical studies when uncertainty is minimized. This talk outlines how process development teams can leverage these guidances to accelerate equivalence demonstrations by integrating advanced analytics, structure–function understanding, and targeted control strategies early in development. We will also highlight how Cytiva’s regulatory services can support teams in interpreting FDA expectations, designing similarity packages, and implementing compliant, efficient development pathways.